Covered already by many folks, but this is a bit embarrassing for Katie Hudson.
- they have changed clinical practice, in this case providing a treatment in a highly unmet medical need space. A therapy for patients that never had one is the definition of changing clinical practice
- we have commercialisation sorted in the US, where it will be expensive for patients but payers have to cover (see first point)
- commercialisation ROW will come in good time
- distribution from our partnership with Acadia is all set.
I'm US-based, work in Biotech and have invested in NEU since 2011. I'm happy I did, but more importantly I'm happy patients have an option when they previously didn't. Working in this space there are very few feel-good stories in our industry. This is one of them.
Katie will figure that out in hindsight I'm sure and we all make mistakes! I thought I had around 2014-18, that's for sure.
Covered already by many folks, but this is a bit embarrassing...
-
- There are more pages in this discussion • 982 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.01 |
Change
-0.715(3.45%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $2.467M | 122.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 436 | $20.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.01 | 40 | 1 |
View Market Depth
| Last trade - 12.47pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |